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f thisW orldwide, the aging population, globalization,rapid urbanization, and population growth havefundamentally changed disease patterns. Non-
ommunicable diseases (NCDs), of which cardiovascular
isease (CVD) accounts for nearly half, have overtaken
ommunicable diseases as the world’s major disease burden.
VD remains the No. 1 global cause of death, accounting for
7.3 million deaths per year, a number that is expected to
row to 23.6 million by 2030. Increasingly, the populations
ffected are those in low- and middle-income countries,
here 80% of these deaths occur, usually at younger ages
han in higher-income countries, and where the human and
nancial resources to address them are most limited (1).
The epidemiological transition occurring is exacerbated by
he lack of vital investment in sustainable health policies to
ddress and curtail the risk factors associated with CVD and
CDs. Recognizing the profound mismatch between the need
or investment in the prevention and control of CVD at the
lobal and national level and the actual resources allocated,
he international CVD community, under the umbrella of the
orld Heart Federation, joined the NCD community to call
or a United Nations (UN) High-level Meeting on Non-
The World Heart Federation, American Heart Association, American
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meeting, heads of state signed a Political Declaration that
committed governments to the development of 4 specific
measures to address the NCD burden in a specific timeline:
1) Recommendations for a global monitoring framework that
included NCD targets to be completed by the end of 2012;
2) development of a plan for an effective multisector partner-
ship by the end of 2012; 3) national NCD plans by 2013; and
4) a comprehensive review to evaluate progress, to take place
in 2014 (2).
Celebrating the 2025 Global NCD
Mortality Target
Celebrating the 1-year anniversary of the passage of the UN
Political Declaration, it is timely that our respective organi-
zations speak with a single voice to advocate for a set of
public health interventions that have the potential to mitigate
and reverse the rising rates of CVD and NCDs. In May 2012,
during the World Health Assembly, Ministers of Health took
the first critical step by agreeing to adopt a global target to
reduce premature NCD mortality 25% by 2025, a target the
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A Call to Save Preventable Deaths From CVD December 4, 2012:2343–8obal CVD community has been advocating since the UN
igh-level Meeting on Non-communicable Diseases (3). We
plaud the World Health Assembly for reaching a consensus
this bold goal.
The UN Political Declaration on NCDs and the recent
solution to reduce premature NCD deaths by 25% are
ndmark achievements for the health and CVD community.
or the first time in history, NCDs have been recognized as a
velopment issue. These targets and indicators have the
tential to address longstanding health challenges, including
e fragmentation of health funding, gaps in the healthcare
frastructure, and the lack of local and reliable data, and will
dress the growing demand for integrated disease manage-
ent. As the Millennium Development Goals come to a close
2015, the CVD community is set to ensure that the single
rgest cause of death—CVD—is addressed. As such, all
levant stakeholders need to be part of the process, putting
timal health at the cornerstone of development.
It is our desire to see heart disease and stroke receive the
tention they deserve. We recognize that the process is
mplex and the time is short, but we have an opportunity to
sure that the commitments made in September 2011 trans-
te into real global, and thus national, action for years to
me. Collaboration among appropriate stakeholders will be
cessary to address this emerging 21st century global health
iority and begin to reverse the devastating toll of CVD and
CDs in our communities.
aintaining the Momentum to Address
ther Targets
first step toward global action has been the passage of the
obal mortality target, which will provide a shared vision on
CDs for all stakeholders and ensure that all targets are
propriately developed to achieve this overarching goal. As
e leading organizations that represent thousands of mem-
rs in nearly every country, and for the millions of individ-
ls with, or at risk of CVD, we are aligning with the broader
CD community in support of a comprehensive set of
ditional targets that will ensure this global reduction is
hieved.
The challenge faced by countries will be to reach agree-
ent concerning the additional targets and indicators to be
rt of the comprehensive monitoring framework to achieve
e overarching global mortality target. In the summer of
10, a World Health Organization (WHO) technical work-
g group developed 10 proposed global targets (Appendix
), which remained virtually unchanged until the spring of
12 (4). At that time, Member States, civil society organi-
tions, and other relevant stakeholders were asked to com-
ent on and make specific recommendations regarding the
obal monitoring framework for NCDs and the specific
rgets and indicators that would be used to guide countries
d measure progress. The original set of 10 targets was
duced before completion of regional consultations and with
mited input of Member States (Appendix B) (5). Calls to
tion from the CVD, NCD, and specific risk-factor commu-
ties did, however, lead to positive changes within this
duced set of targets and included the insertion of a new lorget on physical activity. The inclusion of this target in the
st of recommendations was a milestone in NCD advocacy
forts, ensuring that each of the major risk factors leading to
CDs was addressed. With the release of the third WHO
scussion paper (6), the NCD community’s advocacy efforts
e to be noted as the list of recommended targets for
option includes 10 strong, evidence-based strategies. To-
ther, the Global Cardiovascular Disease Taskforce calls on
e CVD community to endorse and support the top 4 widely
pported exposure targets (Table 1) on physical inactivity,
pertension/blood pressure, dietary salt intake, and tobacco
those required to achieve the overarching goal of a 25%
duction in premature mortality by 2025.
Other, originally proposed targets to address NCDs that
ere dropped in the second WHO discussion paper include
idence-based targets on obesity, trans fat/fat intake,
cohol, and multidrug therapy to prevent and treat CVD
able 2) (7). Although these targets have been included in
e most recent discussion paper, they have been identified as
ving limited support and will need further advocacy to
sure their adoption (7). In addition to supporting the NCD
mmunity in their call for Member States to agree on this
obal set of 10 voluntary targets, we also explicitly call for
ember States to be ambitious and ensure that they
dress those persons at highest risk now by adopting the
ditional exposure and health systems targets currently
der consideration.
To halt and reverse the NCD epidemic, it is paramount that
e CVD burden be adequately addressed, which requires that
ose living with CVD and at highest risk of developing CVD
ve access to treatment and care. The 2011 report by the
HO, Scaling Up Action Against Noncommunicable Dis-
ses: How Much Will It Cost?, details a core set of low-cost
rategies, identified as “Best Buys” that all countries can
plement to prevent and treat NCDs. This list includes
pulation-based measures to address risk factors and spe-
fic individual-based interventions, including a multidrug
erapy regimen of aspirin, a statin, and blood pressure–
ble 1. Suggested Global Targets to Address NCDs With
ide Support (See Appendix C)
Proposed Target
Best
Buy
Recommendation
to Member States
Physical inactivity:
10% Relative reduction in prevalence of
insufficient physical activity
✓ Adopt
Raised blood pressure:
25% Relative reduction in prevalence of
raised blood pressure
✓ Adopt
Salt/sodium intake:
30% Relative reduction in mean
population intake of salt, with aim of
achieving recommended level of
5 g/d (2,000 mg of sodium)
✓ Adopt
Tobacco:
30% Relative reduction in prevalence of
current tobacco smoking
✓ Adopt
NCDs indicate noncommunicable diseases.wering agents to prevent heart disease and stroke and to
tr
(8
gl
pa
C
W
it
an
th
re
dr
th
B
un
co
po
an
N
im
in
id
us
of
in
th
ac
be
hi
th
T
lo
tr
in
ac
ni
in
in
at
ne
w
am
an
he
in
pe
dr
ta
m
im
de
ov
of
ta
ad
re
re
N
w
da
th
im
fo
pa
ac
G
S
R
M
ov
by
ch
an
ch
pu
co
ec
S
ev
Ta
W
5
6
7
8
9
10
2345JACC Vol. 60, No. 22, 2012 Smith et al.
December 4, 2012:2343–8 A Call to Save Preventable Deaths From CVDeat those with, or at highest risk of, heart disease and stroke
). As Member States determine how best to achieve this
obal target, the global CVD community looks to this
ckage of the WHO’s “Best Buys” as a critical way forward.
VD and the WHO Best Buys
ith CVD as the largest single contributor to global mortal-
y, accounting for nearly half of the 36 million NCD deaths,
d with a global cost of nearly US $863 billion, achieving
e global target to reduce premature NCD deaths by 25%
quires that CVD and its risk factors be adequately ad-
essed (9). The Global Cardiovascular Taskforce supports
e set of recommendations identified by the WHO as “Best
uys,” feasible and cost-effective interventions that can be
dertaken regardless of the income level of a country. This
re set of interventions are recommended at 2 levels—
pulation-wide measures to reduce exposure to risk factors
d interventions targeting individuals who already have
CDs or are at high risk of developing them—and are
plemented through a systematic layered approach. Regard-
g population-wide risk factor measures, the WHO has
entified “Best Buys” in the areas of tobacco use, harmful
e of alcohol, salt intake, physical activity, and replacement
trans fat with polyunsaturated fat. Interventions targeting
dividuals include evidence-based, cost-effective medical
erapies alongside counseling, as well as aspirin therapy for
ble 2. Proposed Targets and Indicators to Address NCDs
ith Some Support (See Appendix C)
Proposed Target
Best
Buy
Recommendation
to Member States
Saturated fat intake:
15% Relative reduction in mean
proportion of total energy intake from
saturated fatty acids (SFA), with aim of
achieving a recommended level of
10% of total energy intake
✓ Adopt with
modification
Obesity:
Halt the rise in obesity prevalence
Adopt
Alcohol:
10% Relative reduction in overall
alcohol consumption (especially
hazardous, excessive, and harmful
drinking)
✓ Adopt with
modification
Raised cholesterol:
20% Relative reduction in prevalence of
raised total cholesterol
Adopt
Drug therapy to prevent heart attacks
and strokes:
50% Of eligible people receive drug
therapy to prevent heart attacks and
strokes, and counseling
✓ Adopt
Essential NCD medicines and basic
technologies to treat major NCDs:
80% Availability of basic technologies
and generic essential medicines
required to treat major NCDs in both
public and private facilities
Adopt
NCDs indicate noncommunicable diseases.ute myocardial infarction (10). mOn the occasion of the UN High-level Meeting in Septem-
r 2011, the WHO introduced a tool for low-, middle-, and
gh-income countries to guide and estimate the feasibility of
e implemention of this core set of NCD interventions (8).
he cost of the interventions is US$11.4 billion per year in
w- and middle-income settings. Yearly, per person, this
anslates to US$1 a day (US$0.43–US$0.90) across low-
come countries and US$3 a day (US$0.54–US$2.93)
ross middle-income countries (11).
Several of the 10 targets being supported by the NCD commu-
ty have been identified within this core set of “Best Buy”
terventions and are at risk of failing to be adopted as global targets,
cluding the evidence-based drug therapy regimen to address those
highest risk for developing CVD. Studies have indicated that
arly 17.9 million deaths could be averted over a 10-year period
ith the implementation of multidrug therapy (11). The cost would
ount to just over US$1 a day annually. Beyond the lives saved
d the life-years extended, reducing the mortality rate for ischemic
art disease and stroke by 10% would also reduce economic losses
low- and middle-income countries by an estimated US$25 billion
r year (12). Drug therapy, singly or in combination with multiple
ugs, is documented to be a concrete investment and should be a
rget to be accomplished.
As Member States look to finalize targets in the coming
onths, doubt regarding country-level compliance in the
plementation of NCD interventions, as a result of under-
veloped monitoring and surveillance systems, must not
ershadow the real, cost-effective, and feasible solutions
fered by the WHO “Best Buys.” Collection of data, for all
rgets, remains a critical issue that can, and should, be
dressed through the Global Monitoring Framework. It is
cognized that target levels may vary slightly in different
gions of the world. As such, when considering national
CD action plans, all targets will require adequate and
ell-developed indicators that encourage the improvement of
ta at the country level and provide an impetus to countries
at have the tools to collect and monitor data. Moreover,
proved healthcare delivery and an expanded health work-
rce with coordination of local and national approaches are
ramount in building comprehensive health systems to
hieve this end.
lobal Cardiovascular Taskforce
ummary Position: Prevention,
isk Factors, and Treatment
ember States have taken the first step and set a bold
erarching goal of reducing mortality from NCDs by 25%
2025. We now have the opportunity to make meaningful
anges in our countries by adopting evidence-based targets
d implementing tactics that will guide health policy,
ronic disease plans and, ultimately, resources for national
blic health interventions. Many of these are feasible and
st-effective. Reducing NCDs are central to a country’s
onomic growth. As such, we respectfully request Member
tates to consider our recommendations and adopt the
idence-based targets to address CVD and NCDs and avert
illions of deaths by 2025.
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A Call to Save Preventable Deaths From CVD December 4, 2012:2343–8ppendix A. Original Set of Targets
Outcome Targets Indicator Source
emature mortality from NCDs
25% Relative reduction in overall mortality from
CVD, cancer, diabetes, or chronic respiratory disease
Unconditional probability of dying between ages
30 and 70 y from CVD, cancer, diabetes, or
chronic respiratory disease
Civil registration system, with medical
certification of cause of death, or
survey with verbal autopsy
abetes
10% Relative reduction in the prevalence of diabetes
mellitus (elevated blood glucose level 7.0 mmol/L
[26 mg/dL] or on treatment for diabetes)
Age-standardized prevalence of diabetes mellitus
among persons age 25 y (defined as fasting
plasma glucose 7.0 mmol/L [126 mg/dL] or on
treatment for diabetes)
National survey (with measurement)
posure Targets
bacco smoking
40% Relative reduction in prevalence of current
tobacco smoking
Age-standardized prevalence of current tobacco
smoking among persons age 15 y
National survey
cohol
10% Relative reduction in alcohol per capita
consumption among persons age 15 y
Per capita consumption of pure liters of alcohol
among persons age 15 y
Official statistics and reporting systems
for production, import, export, and sale
or taxation data and national survey
etary salt intake
Mean adult population intake of salt 5 g/d (2,000
mg of sodium)
Age-standardized mean population intake of salt
per day in grams
National survey (with measurement)
ood pressure/hypertension
25% Relative reduction in the prevalence of elevated
blood pressure (defined as systolic blood pressure
140 mm Hg and/or diastolic blood pressure
90 mm Hg)
National survey (with measurement)
esity
No increase in obesity prevalence
Age-standardized prevalence of obesity (defined
as BMI 30 kg/m2) in persons age 25 y
National survey (with measurement)
evention of heart attack and stroke
80% Coverage of multidrug therapy (including
glycemic control) for people age 30 y with a 10-y
risk of heart attack or stroke 30%, or existing CVD
Percentage of people age 30 y with a 10-y
risk of heart attack or stroke 30%, or existing
CVD who are currently on multidrug therapy
(including glycemic control)
National survey (with measurement)
rvical cancer screening
80% Of women between ages 30 and 49 y screened
for cervical cancer at least once
Prevalence of women between ages 30 and
49 y screened for cervical cancer at least once
National survey; health facility data
imination of industrially produced trans fatty acids
(PHVO) from the food supply
Adoption of national policies that eliminate
PHVOs in the food supply
Policy reviewNCDs indicate noncommunicable diseases; CVD, cardiovascular disease; BMI, body mass index; and PHVO, partially hydrogenated vegetable oil.ppendix B. Reduced List of Targets
Outcome Targets Indicator Data Source(s)
ortality from NCDs
25% Relative reduction in overall mortality from CVD,
cancer, diabetes, or chronic respiratory disease
Unconditional probability of dying between ages
30 and 70 y from CVD, cancer, diabetes, or chronic
respiratory disease
Civil registration system, with medical
certification of cause of death, or
survey with verbal autopsy
ood pressure/hypertension
25% Relative reduction in the prevalence of elevated blood
pressure (defined as systolic blood pressure 140 mm Hg
and/or diastolic blood pressure
90 mm Hg)
25% relative reduction in the prevalence of elevated
blood pressure (defined as systolic blood pressure
140 mm Hg and/or diastolic blood pressure
90 mm Hg)
National survey (with measurement)
bacco smoking
40% Relative reduction in prevalence of current tobacco
smoking
Age-standardized prevalence of current tobacco
smoking among persons age 15 y
National survey
etary salt intake
Mean adult population intake of salt 5 g/d (2,000 mg of
sodium)
Age-standardized mean population intake of salt per
day in grams
National survey (with measurement)
ysical inactivity
10% Relative reduction in prevalence of insufficient
physical activity in adults aged 18 y
Age-standardized prevalence of obesity (defined as
BMI 30 kg/m2) in persons age 25 y
National surveyNCDs indicate noncommunicable diseases; CVD, cardiovascular disease; and BMI, body mass index.
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December 4, 2012:2343–8 A Call to Save Preventable Deaths From CVDppendix C. Current Set of Targets
Outcome Targets Indicator Data Source(s)
emature mortality from NCDs
25% Relative reduction in overall mortality from
CVD, cancer, diabetes, or chronic respiratory
disease
Unconditional probability of dying between ages 30–70
y from CVD, cancer, diabetes, or chronic respiratory
disease
Civil registration system, with medical
certification of cause of death, or
survey with verbal autopsy
posure Targets
cohol
10% Relative reduction in overall alcohol
consumption (including hazardous and harmful
drinking)
Total (recorded and unrecorded) alcohol per capita
(15 y) consumption within a calendar year in liters of
pure alcohol
Official statistics and reporting systems
for production, import, export, and
sales or taxation data
t intake
15% Relative reduction in mean proportion of
total energy intake from saturated fatty acids
(SFA), with aim of achieving recommended level
of 10% of total energy intake
Age-standardized mean proportion of total energy intake
from saturated fatty acids (SFA) in adults aged 18 y
National survey
esity
Halt the rise in obesity prevalence
Age-standardized prevalence of obesity among adults
aged 18 y
National survey (with measurement)
ysical inactivity
10% Relative reduction in prevalence of
insufficient physical activity
Age-standardized prevalence of insufficient physical
activity in adults aged 18 y
National survey
ised blood pressure
25% Relative reduction in prevalence of raised
blood pressure
Age-standardized prevalence of raised blood pressure
among adults aged 18 y
National survey (with measurement)
ised cholesterol
20% Relative reduction in prevalence of raised
total cholesterol
Age-standardized prevalence of raised total cholesterol
among adults aged 18 y
National survey (with measurement)
lt/sodium intake
30% Relative reduction in mean population intake
of salt, with aim of achieving recommended level
of 5 g/d (2,000 mg of sodium)
Age-standardized mean adult (aged 18 y) population
intake of salt per day
National survey (with measurement)
bacco
30% Relative reduction in prevalence of current
tobacco smoking
Age-standardized prevalence of current tobacco
smoking among persons aged 15 y
National survey
alth Systems Response Targets
ug therapy to prevent heart attacks and strokes
50% Of eligible people receive drug therapy to
prevent heart attacks and strokes, and counseling
Drug therapy to prevent heart attacks and strokes
(including glycemic control), and counseling for people
aged 40 y with a 10-year cardiovascular risk 30%
(includes those with existing cardiovascular disease)
National survey
sential NCD medicines and basic technologies to
at major NCDs
80% Availability of basic technologies and generic
essential medicines required to treat major NCDs
in both public and private facilities
Availability of basic technologies and generic essential
medicines required to treat major NCDs in public and
private sector facilities, including primary care facilities
Facility dataNCDs indicate noncommunicable diseases; CVD, cardiovascular disease.
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